EICHORCondition: Eosinophilic Esophagitis · Sponsor: Ellodi Pharmaceuticals, LP
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a 2-part randomized, double-blind, placebo-controlled study followed by an open-label extension (OLE) of APT-1011 in adults with EoE. Part A will evaluate the efficacy and safety of APT-1011 3 mg administered hora somni (HS; at bedtime) for the induction of response to treatment (histologic and symptomatic) over 12 weeks. Part B will evaluate histological relapse-free status in patients re-randomized to continue APT-1011 or placebo (active treatment withdrawal) until Week 52. Part C, the OLE, will continue until regulatory approval of APT-1011 or Sponsor termination of the study.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Pinnacle Research Group, LLC | Anniston, Alabama, United States | — |
| Gut P.C., dba; Digestive Health Specialists of the Southeast | Dothan, Alabama, United States | — |
| East View Medical Research, LLC | Mobile, Alabama, United States | — |
| Del Sol Research Management, LLC | Tucson, Arizona, United States | — |
| Preferred Research Partners Inc. | Little Rock, Arkansas, United States | — |
| Arkansas Gastroenterology | North Little Rock, Arkansas, United States | — |
| Camarillo Endoscopy Center | Camarillo, California, United States | — |
| Hope Clinical Research | Canoga Park, California, United States | — |
| Facey Medical Foundation | Mission Hills, California, United States | — |
| United Medical Doctors | Murrieta, California, United States | — |
| Medical Associates Research Group | San Diego, California, United States | — |
| Asthma and Allergy Associates, PC | Colorado Springs, Colorado, United States | — |
+ 44 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04281108